Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer
28 févr. 2024 08h00 HE
|
Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today...
Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
06 févr. 2024 09h50 HE
|
Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, Mass., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer...
Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares
02 févr. 2024 16h01 HE
|
Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, Mass., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today...
Corbus Pharmaceuticals Announces Pricing of Public Offering
31 janv. 2024 09h19 HE
|
Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today...
Corbus Pharmaceuticals Announces Proposed Public Offering
30 janv. 2024 18h55 HE
|
Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, Mass., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today...
CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024
26 janv. 2024 07h30 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Q3W schedule of CRB-701 (SYS6002) demonstrates a 43% ORR and 71% DCR at predicted therapeutically relevant dosesAll assessable nectin-4 positive study participants with mUC and cervical cancer treated...
Phase 1 Clinical Data for SYS6002 (CRB-701) to be presented at 2024 ASCO GU
23 janv. 2024 08h00 HE
|
Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, Mass., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), announced today that the abstract for the first-in-human Phase 1...
Corbus Pharmaceuticals Announces FDA Clearance of IND Application for its anti-αvβ8 monoclonal antibody (CRB-601)
09 janv. 2024 08h00 HE
|
Corbus Pharmaceuticals Holdings, Inc.
CRB-601 is designed to block the activation of latent TGFβ in the tumor microenvironmentPhase 1 clinical study set to commence H1 2024Pre-clinical data presented demonstrates robust anti-tumor...
Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO GU
18 déc. 2023 08h00 HE
|
Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, Mass., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today...
Corbus Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
07 nov. 2023 08h00 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Data from dose escalation study for CRB-701, a Nectin-4 ADC to treat solid tumors, on track for release in early 2024 along with start of U.S./EU StudyIND Submission for CRB-601, an αvβ8 Monoclonal...